{"id":"danazol","rwe":[{"pmid":"41905994","year":"2026","title":"Identification of biomarkers associated with endoplasmic reticulum stress-related cell death in osteoporosis based on bulk and single-cell transcriptomic analyses and experimental validation.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"41880096","year":"2026","title":"Single-Cell Transcriptomics Reveals Biomarkers for NK Cell Dysfunction in Endometriosis-Associated Immune Dysregulation.","finding":"","journal":"Mediators of inflammation","studyType":"Clinical Study"},{"pmid":"41842707","year":"2026","title":"Therapeutic Targets for Lung Squamous Cell Carcinoma: Proteome-Wide Mendelian Randomization and Potential Drug Prediction.","finding":"","journal":"The clinical respiratory journal","studyType":"Clinical Study"},{"pmid":"41838173","year":"2026","title":"MPIG6B-related thrombocytopenia and myelofibrosis: A case report.","finding":"","journal":"Annals of hematology","studyType":"Clinical Study"},{"pmid":"41743825","year":"2026","title":"Abdominal Wall Endometriosis Postcesarean Section: Diagnosis, Surgical Management, and Case Study of Extensive Uterine Adhesion.","finding":"","journal":"Case reports in obstetrics and gynecology","studyType":"Clinical Study"}],"_fda":{"id":"241f23e1-4b4b-4adb-e063-6394a90adcc5","set_id":"55ad6325-16f6-4f0c-a1dc-734847052d0b","openfda":{"nui":["N0000175824","N0000000146","M0001109"],"upc":["0362135477608","0362135475604","0362135476601"],"unii":["N29QWW3BUO"],"route":["ORAL"],"rxcui":["197554","197555","197556"],"spl_id":["241f23e1-4b4b-4adb-e063-6394a90adcc5"],"brand_name":["Danazol"],"spl_set_id":["55ad6325-16f6-4f0c-a1dc-734847052d0b"],"package_ndc":["62135-475-60","62135-476-60","62135-477-60"],"product_ndc":["62135-475","62135-476","62135-477"],"generic_name":["DANAZOL"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Androstanes [CS]"],"substance_name":["DANAZOL"],"pharm_class_epc":["Androgen [EPC]"],"pharm_class_moa":["Androgen Receptor Agonists [MoA]"],"manufacturer_name":["Chartwell RX, LLC."],"application_number":["ANDA077246"],"is_original_packager":[true]},"version":"3","description":["DESCRIPTION Danazol is a synthetic steroid derived from ethisterone. It is a white to pale yellow crystalline powder, practically insoluble or insoluble in water, and sparingly soluble in alcohol. Chemically, danazol is 17α-Pregna-2,4-dien-20-yno [2,3- d ]- isoxazol-17-ol. The molecular formula is C 22 H 27 NO 2 . It has a molecular weight of 337.46 and the following structural formula: Danazol capsules for oral administration contain 50 mg, 100 mg or 200 mg danazol. Inactive Ingredients: anhydrous lactose, lactose monohydrate, magnesium stearate, pregelatinized starch, sodium lauryl sulfate, talc. Capsule shells for 200 mg danazol contain D&C Yellow #10, FD&C Red #40, D&C Red #28, gelatin, and titanium dioxide. Capsule shells for 50 mg and 100 mg danazol contain D&C Yellow # 10, FD&C Red # 40, gelatin, and titanium dioxide. The capsule imprinting ink contains: shellac glaze in ethanol, iron oxide black, n-butyl alcohol, propylene glycol, ethanol, methanol, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake, and D&C Yellow No. 10 Aluminum Lake. image description"],"precautions":["PRECAUTIONS Because danazol capsules may cause some degree of fluid retention, conditions that might be influenced by this factor, such as epilepsy, migraine, or cardiac or renal dysfunction, polycythemia and hypertension require careful observation. Use with caution in patients with diabetes mellitus. Since hepatic dysfunction manifested by modest increases in serum transaminases levels has been reported in patients treated with danazol capsules, periodic liver function tests should be performed (see WARNINGS and ADVERSE REACTIONS ). Administration of danazol has been reported to cause exacerbation of the manifestations of acute intermittent porphyria (see CONTRAINDICATIONS ). Laboratory monitoring of the hematologic state should be considered. Drug Interactions: Prolongation of prothrombin time occurs in patients stabilized on warfarin. Therapy with danazol may cause an increase in carbamazepine levels in patients taking both drugs. Danazol can cause insulin resistance. Caution should be exercised when used with antidiabetic drugs. Danazol may raise the plasma levels of cyclosporin and tacrolimus, leading to an increase of the renal toxicity of these drugs. Monitoring of systemic concentrations of these drugs and appropriate dose adjustments may be needed when used concomitantly with danazol. Danazol can increase the calcemic response to synthetic vitamin D analogs in primary hypoparathyroidism. The risk of myopathy and rhabdomyolysis is increased by concomitant administration of danazol with statins such as simvastatin, atorvastatin and lovastatin. Caution should be exercised if used concomitantly. Consult the product labeling for statin drugs for specific information on dose restrictions in presence of danazol. Laboratory Tests: Danazol treatment may interfere with laboratory determinations of testosterone, androstenedione and dehydroepiandrosterone. Other metabolic events include a reduction in thyroid binding globulin and T4 with increased uptake of T3, but without disturbance of thyroid stimulating hormone or of free thyroxin index. Carcinogenesis, Mutagenesis, Impairment of Fertility: Current data are insufficient to assess the carcinogenicity of danazol. Pregnancy, Teratogenic Effects: (See CONTRAINDICATIONS .) Danazol administered orally to pregnant rats from the 6th through the 15th day of gestation at doses up to 250 mg/kg/day (7-15 times the human dose) did not result in drug-induced embryotoxicity or teratogenicity, nor difference in litter size, viability or weight of offspring compared to controls. In rabbits, the administration of danazol on days 6-18 of gestation at doses of 60 mg/kg/day and above (2-4 times the human dose) resulted in inhibition of fetal development. Nursing Mothers: (See CONTRAINDICATIONS . ) Pediatric Use: Safety and effectiveness in pediatric patients have not been established. Geriatric Use: Clinical studies of danazol capsules did not include sufficient numbers of subjects aged 65 and over to determine the safety and effectiveness of Danocrine in elderly patients."],"how_supplied":["HOW SUPPLIED Danazol Capsules USP, 50 mg are available as maize opaque/white opaque capsules imprinted with logo \"LANNETT\" on the cap and \"1392\" on the body and are supplied in: Bottles of 60 (NDC 62135-475-60) Danazol Capsules USP, 100 mg are available as maize opaque/maize opaque capsules imprinted with logo \"LANNETT\" on the cap and \"1368\" on the body and are supplied in: Bottles of 60 (NDC 62135-476-60) Danazol Capsules USP, 200 mg are available as orange opaque/orange opaque capsules imprinted with logo \"LANNETT\" on the cap and \"1369\" on the body and are supplied in: Bottles of 60 (NDC 62135-477-60) Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in a well-closed container with a child-resistant closure as defined in the USP. Manufactured for: Chartwell RX, LLC. Congers, NY 10920 L71285 Rev. 02/2023"],"boxed_warning":["WARNINGS Use of danazol in pregnancy is contraindicated. A sensitive test (e.g., beta subunit test if available) capable of determining early pregnancy is recommended immediately prior to start of therapy. Additionally a non-hormonal method of contraception should be used during therapy. If a patient becomes pregnant while taking danazol, administration of the drug should be discontinued and the patient should be apprised of the potential risk to the fetus. Exposure to danazol in utero may result in androgenic effects on the female fetus; reports of clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been received (see PRECAUTIONS: Pregnancy, Teratogenic Effects ). Thromboembolism, thrombotic and thrombophlebitic events including sagittal sinus thrombosis and life-threatening or fatal strokes have been reported. Experience with long-term therapy with danazol is limited. Peliosis hepatis and benign hepatic adenoma have been observed with long-term use. Peliosis hepatis and hepatic adenoma may be silent until complicated by acute, potentially life-threatening intraabdominal hemorrhage. The physician therefore should be alert to this possibility. Attempts should be made to determine the lowest dose that will provide adequate protection. If the drug was begun at a time of exacerbation of hereditary angioneurotic edema due to trauma, stress or other cause, periodic attempts to decrease or withdraw therapy should be considered. Danazol has been associated with several cases of benign intracranial hypertension also known as pseudotumor cerebri. Early signs and symptoms of benign intracranial hypertension include papilledema, headache, nausea and vomiting, and visual disturbances. Patients with these symptoms should be screened for papilledema and, if present, the patients should be advised to discontinue danazol immediately and be referred to a neurologist for further diagnosis and care."],"effective_time":"20241010","adverse_reactions":["ADVERSE REACTIONS The following events have been reported in association with the use of danazol capsules: Androgen like effects include weight gain, acne and seborrhea. Mild hirsutism, edema, hair loss, voice change, which may take the form of hoarseness, sore throat or of instability or deepening of pitch, may occur and may persist after cessation of therapy. Hypertrophy of the clitoris is rare. Other possible endocrine effects are menstrual disturbances including spotting, alteration of the timing of the cycle and amenorrhea. Although cyclical bleeding and ovulation usually return within 60-90 days after discontinuation of therapy with danazol capsules, persistent amenorrhea has occasionally been reported. Flushing, sweating, vaginal dryness and irritation and reduction in breast size, may reflect lowering of estrogen. Nervousness and emotional lability have been reported. In the male a modest reduction in spermatogenesis may be evident during treatment. Abnormalities in semen volume, viscosity, sperm count, and motility may occur in patients receiving long-term therapy. Hepatic dysfunction, as evidenced by reversible elevated serum enzymes and/or jaundice, has been reported in patients receiving a daily dosage of danazol capsules of 400 mg or more. It is recommended that patients receiving danazol capsules be monitored for hepatic dysfunction by laboratory tests and clinical observation. Serious hepatic toxicity including cholestatic jaundice, peliosis hepatis, hepatic adenoma, hepatocellular injury, hepatocellular jaundice and hepatic failure have been reported (see WARNINGS and PRECAUTIONS ). Abnormalities in laboratory tests may occur during therapy with danazol capsules including CPK, glucose tolerance, glucagon, thyroid binding globulin, sex hormone binding globulin, other plasma proteins, lipids and lipoproteins. The following reactions have been reported, a causal relationship to the administration of danazol capsules has neither been confirmed nor refuted; allergic: urticaria, pruritus and rarely, nasal congestion; CNS effects: headache, nervousness and emotional lability, dizziness and fainting, depression, fatigue, sleep disorders, tremor, paresthesias, weakness, visual disturbances, and rarely, benign intracranial hypertension, anxiety, changes in appetite, chills, and rarely convulsions, Guillain-Barre syndrome; gastrointestinal: gastroenteritis, nausea, vomiting, constipation, and rarely, pancreatitis and splenic peliosis; musculoskeletal: muscle cramps or spasms, or pains, joint pain, joint lockup, joint swelling, pain in back, neck, or extremities, and rarely, carpal tunnel syndrome which may be secondary to fluid retention; genitourinary: hematuria, prolonged posttherapy amenorrhea; hematologic: an increase in red cell and platelet count. Reversible erythrocytosis, leukocytosis or polycythemia may be provoked. Eosinophilia, leukopenia and thrombocytopenia have also been noted. Skin: rashes (maculopapular, vesicular, papular, purpuric, petechial), and rarely, sun sensitivity, Stevens-Johnson syndrome and erythema multiforme; other: increased insulin requirements in diabetic patients, change in libido, myocardial infarction, palpitation, tachycardia, elevation in blood pressure, interstitial pneumonitis, and rarely, cataracts, bleeding gums, fever, pelvic pain, nipple discharge. Malignant liver tumors have been reported in rare instances, after long-term use."],"contraindications":["CONTRAINDICATIONS Danazol capsules should not be administered to patients with: Undiagnosed abnormal genital bleeding. Markedly impaired hepatic, renal, or cardiac function. Pregnancy (see WARNINGS ). Breast feeding. Porphyria-Danazol capsules can induce ALA synthetase activity and hence porphyrin metabolism. Androgen-dependent tumor. Active thrombosis or thromboembolic disease and history of such events. Hypersensitivity to danazol."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Danazol suppresses the pituitary-ovarian axis. This suppression is probably a combination of depressed hypothalamic-pituitary response to lowered estrogen production, the alteration of sex steroid metabolism, and interaction of danazol with sex hormone receptors. The only other demonstrable hormonal effect is weak androgenic activity. Danazol depresses the output of both follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Recent evidence suggests a direct inhibitory effect at gonadal sites and a binding of danazol to receptors of gonadal steroids at target organs. In addition, danazol has been shown to significantly decrease IgG, IgM and IgA levels, as well as phospholipid and IgG isotope autoantibodies in patients with endometriosis and associated elevations of autoantibodies, suggesting this could be another mechanism by which it facilitates regression of the disease. In the treatment of endometriosis, danazol alters the normal and ectopic endometrial tissue so that it becomes inactive and atrophic. Complete resolution of endometrial lesions occurs in the majority of cases. Changes in vaginal cytology and cervical mucus reflect the suppressive effect of danazol on the pituitary-ovarian axis. Changes in the menstrual pattern may occur. Generally, the pituitary-suppressive action of danazol is reversible. Ovulation and cyclic bleeding usually return within 60 to 90 days when therapy with danazol is discontinued. In the treatment of hereditary angioedema, danazol at effective doses prevents attacks of the disease characterized by episodic edema of the abdominal viscera, extremities, face, and airway which may be disabling and, if the airway is involved, fatal. In addition, danazol corrects partially or completely the primary biochemical abnormality of hereditary angioedema by increasing the levels of the deficient C1 esterase inhibitor (C1EI). As a result of this action the serum levels of the C4 component of the complement system are also increased."],"indications_and_usage":["INDICATIONS AND USAGE Endometriosis. Danazol capsules are indicated for the treatment of endometriosis amenable to hormonal management. Hereditary Angioedema. Danazol capsules are indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females."],"spl_unclassified_section":["Pharmacokinetics Absorption: After oral administration of a 400 mg dose to healthy male volunteers, peak plasma concentrations of danazol are reached between 2 and 8 hours, with a median T max value of 4 hours. Steady state conditions are observed following 6 days of twice daily dosing of danazol capsules. The pharmacokinetic parameters for danazol capsules after administering a 400 mg oral dose to healthy males are summarized in the following table: Parameters Mean ± SD (n=15) C max (ng/mL) 69.6 ± 29.9 T max (h) 2.47 ± 1.62 AUC 0-∞ (ng*h/mL) 601 ± 181 t 1/2 (h) 9.70 ± 3.29 Total Body Clearance (L/h) 727 ± 221 The pharmacokinetic parameters for danazol capsules after oral administration of 100, 200 and 400 mg single doses to healthy female volunteers are summarized in the following table: Dose (mg) Mean C max ± SD (ng/mL) Mean T max (h) Mean AUC 0-∞ ± SD (ng*h/mL) Fasting Fed Fasting Fed Fasting Fed 100 45.9 ± 23.9 113.8 ± 46.0 1-8 2-6 484 ± 263 741 ± 265 200 63.8 ± 27.7 159 ± 57.3 1-6 2-4 681 ± 363 1252 ± 307 400 60.4 ± 30.0 253.7 ± 105.5 1-6 2-4 754 ± 443 1851 ± 605 Dose proportionality: Bioavailability studies indicate that blood levels do not increase proportionally with increases in the administered dose. Single dose administration of danazol capsules in healthy female volunteers found that a 4-fold increase in dose produced only a 1.6 and 2.5-fold increase in AUC and a 1.3 and 2.2-fold increase in C max in the fasted and fed state, respectively. A similar degree of non-dose proportionality was observed at steady state. Food Effect: Single dose administration of 100 mg and 200 mg capsules of danazol to female volunteers showed that both the extent of availability and the maximum plasma concentration increased by 3 to 4 fold, respectively, following a meal (> 30 grams of fat), when compared to the fasted state. Further, food also delayed mean time to peak concentration of danazol by about 30 minutes. Even after multiple dosing under less extreme food/fasting conditions, there remained approximately a 2 to 2.5 fold difference in bioavailability between the fed and fasted states. Distribution: Danazol is lipophilic and can partition into cell membranes, indicating the likelihood of distribution into deep tissue compartments. Metabolism and Excretion: Danazol appears to be metabolized and the metabolites are eliminated by renal and fecal pathways. The two primary metabolites excreted in the urine are 2-hydroxymethyl danazol and ethisterone. At least ten different products were identified in feces. The reported elimination half-life of danazol is variable across studies. The mean half-life of danazol in healthy males is 9.7 h. After 6 months of 200 mg three times a day dosing in endometriosis patients, the half-life of danazol was reported as 23.7 hours.","A temporary alteration of lipoproteins in the form of decreased high density lipoproteins and possibly increased low density lipoproteins has been reported during danazol therapy. These alterations may be marked, and prescribers should consider the potential impact on the risk of atherosclerosis and coronary artery disease in accordance with the potential benefit of the therapy to the patient. Patients should be watched closely for signs of androgenic effects some of which may not be reversible even when drug administration is stopped."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Endometriosis. In moderate to severe disease, or in patients infertile due to endometriosis, a starting dose of 800 mg given in two divided doses is recommended. Amenorrhea and rapid response to painful symptoms is best achieved at this dosage level. Gradual downward titration to a dose sufficient to maintain amenorrhea may be considered depending upon patient response. For mild cases, an initial daily dose of 200 mg to 400 mg given in two divided doses is recommended and may be adjusted depending on patient response. Therapy should begin during menstruation. Otherwise, appropriate tests should be performed to ensure that the patient is not pregnant while on therapy with danazol capsules (see CONTRAINDICATIONS and WARNINGS ). It is essential that therapy continue uninterrupted for 3 to 6 months but may be extended to 9 months if necessary. After termination of therapy, if symptoms recur, treatment can be reinstituted. Hereditary Angioedema. The dosage requirements for continuous treatment of hereditary angioedema with danazol capsules should be individualized on the basis of the clinical response of the patient. It is recommended that the patient be started on 200 mg, two or three times a day. After a favorable initial response is obtained in terms of prevention of episodes of edematous attacks, the proper continuing dosage should be determined by decreasing the dosage by 50% or less at intervals of one to three months or longer if frequency of attacks prior to treatment dictates. If an attack occurs, the daily dosage may be increased by up to 200 mg. During the dose adjusting phase, close monitoring of the patient's response is indicated, particularly if the patient has a history of airway involvement."],"spl_product_data_elements":["Danazol Danazol ANHYDROUS LACTOSE LACTOSE MONOHYDRATE MAGNESIUM STEARATE STARCH, CORN SODIUM LAURYL SULFATE TALC D&C YELLOW NO. 10 FD&C RED NO. 40 GELATIN TITANIUM DIOXIDE SHELLAC ALCOHOL FERROSOFERRIC OXIDE BUTYL ALCOHOL PROPYLENE GLYCOL METHYL ALCOHOL FD&C BLUE NO. 2 FD&C BLUE NO. 1 ALUMINUM OXIDE DANAZOL DANAZOL maize opaque cap white opaque body LANNETT;1392 Danazol Danazol ANHYDROUS LACTOSE LACTOSE MONOHYDRATE MAGNESIUM STEARATE STARCH, CORN SODIUM LAURYL SULFATE TALC D&C YELLOW NO. 10 FD&C RED NO. 40 GELATIN TITANIUM DIOXIDE SHELLAC ALCOHOL FERROSOFERRIC OXIDE BUTYL ALCOHOL PROPYLENE GLYCOL METHYL ALCOHOL FD&C BLUE NO. 2 FD&C BLUE NO. 1 ALUMINUM OXIDE DANAZOL DANAZOL maize opaque cap and body LANNETT;1368 Danazol Danazol SHELLAC ANHYDROUS LACTOSE LACTOSE MONOHYDRATE MAGNESIUM STEARATE STARCH, CORN SODIUM LAURYL SULFATE TALC D&C YELLOW NO. 10 FD&C RED NO. 40 D&C RED NO. 28 GELATIN TITANIUM DIOXIDE ALCOHOL FERROSOFERRIC OXIDE BUTYL ALCOHOL PROPYLENE GLYCOL METHYL ALCOHOL FD&C BLUE NO. 2 FD&C BLUE NO. 1 ALUMINUM OXIDE DANAZOL DANAZOL orange opaque cap and body LANNETT;1369"],"spl_unclassified_section_table":["
ParametersMean ± SD (n=15)
C max (ng/mL) 69.6 ± 29.9
T max (h) 2.47 ± 1.62
AUC 0-∞ (ng*h/mL) 601 ± 181
t 1/2 (h) 9.70 ± 3.29
Total Body Clearance (L/h)727 ± 221
","
Dose (mg) Mean C max ± SD (ng/mL) Mean T max (h) Mean AUC 0-∞ ± SD (ng*h/mL)
FastingFedFastingFedFasting Fed
10045.9 ± 23.9 113.8 ± 46.0 1-82-6 484 ± 263 741 ± 265
20063.8 ± 27.7 159 ± 57.31-62-4681 ± 363 1252 ± 307
400 60.4 ± 30.0 253.7 ± 105.5 1-62-4754 ± 443 1851 ± 605
"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Danazol Capsules USP, 50 mg- NDC 62135-475-60 -60's bottle label Danazol Capsules USP, 100 mg- NDC 62135-476-60 -60's bottle label Danazol Capsules USP, 200 mg- NDC 62135-477-60 -60's bottle label image description image description image description"]},"tags":[{"label":"Androgen","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sex hormone-binding globulin","category":"target"},{"label":"SHBG","category":"gene"},{"label":"CYP2C9","category":"gene"},{"label":"NR3C1","category":"gene"},{"label":"G03XA01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Endometriosis","category":"indication"},{"label":"Fibrocystic breast changes","category":"indication"},{"label":"Hereditary Angioedema Prevention","category":"indication"},{"label":"Approved 1970s","category":"decade"},{"label":"Estrogen Antagonists","category":"pharmacology"},{"label":"Hormone Antagonists","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNINGS Use of danazol in pregnancy is contraindicated. A sensitive test (e.g., beta subunit test if available) capable of determining early pregnancy is recommended immediately prior to start of therapy. Additionally a non-hormonal method of contraception should be used during therapy. If a patient becomes pregnant while taking danazol, administration of the drug should be discontinued and the patient should be apprised of the potential risk to the fetus. Exposure to danazol in utero may result in androgenic effects on the female fetus; reports of clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been received (see PRECAUTIONS: Pregnancy, Teratogenic Effects ). Thromboembolism, thrombotic and thrombophlebitic events including sagittal sinus thrombosis and life-threatening or fatal strokes have been reported. Experience with long-term therapy with danazol is limited. Peliosis hepatis and benign hepatic adenoma have been observed with long-term use. Peliosis hepatis and hepatic adenoma may be silent until complicated by acute, potentially life-threatening intraabdominal hemorrhage. The physician therefore should be alert to this possibility. Attempts should be made to determine the lowest dose that will provide adequate protection. If the drug was begun at a time of exacerbation of hereditary angioneurotic edema due to trauma, stress or other cause, periodic attempts to decrease or withdraw therapy should be considered. Danazol has been associated with several cases of benign intracranial hypertension also known as pseudotumor cerebri. Early signs and symptoms of benign intracranial hypertension include papilledema, headache, nausea and vomiting, and visual disturbances. Patients with these symptoms should be screened for papilledema and, if present, the patients should be advised to discontinue danazol immediately and be referred to a neurologist for further diagnosis and care."],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"437 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"403 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"310 reports"},{"date":"","signal":"ANGIOEDEMA","source":"FDA FAERS","actionTaken":"218 reports"},{"date":"","signal":"HEREDITARY ANGIOEDEMA","source":"FDA FAERS","actionTaken":"217 reports"},{"date":"","signal":"HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"217 reports"},{"date":"","signal":"DRUG INTOLERANCE","source":"FDA FAERS","actionTaken":"206 reports"},{"date":"","signal":"DRUG INEFFECTIVE FOR UNAPPROVED INDICATION","source":"FDA FAERS","actionTaken":"203 reports"},{"date":"","signal":"DYSPHONIA","source":"FDA FAERS","actionTaken":"203 reports"},{"date":"","signal":"SWELLING FACE","source":"FDA FAERS","actionTaken":"203 reports"}],"drugInteractions":[{"url":"/drug/dicoumarol","drug":"dicoumarol","action":"Avoid combination","effect":"May interact with Dicumarol","source":"DrugCentral","drugSlug":"dicoumarol"},{"url":"/drug/phenprocoumon","drug":"phenprocoumon","action":"Avoid combination","effect":"May interact with Phenprocoumon","source":"DrugCentral","drugSlug":"phenprocoumon"},{"url":"/drug/simvastatin","drug":"simvastatin","action":"Avoid combination","effect":"May interact with Simvastatin","source":"DrugCentral","drugSlug":"simvastatin"},{"url":"/drug/tacrolimus","drug":"tacrolimus","action":"Monitor closely","effect":"May interact with Tacrolimus","source":"DrugCentral","drugSlug":"tacrolimus"},{"url":"/drug/warfarin","drug":"warfarin","action":"Monitor closely","effect":"May interact with Warfarin","source":"DrugCentral","drugSlug":"warfarin"}],"commonSideEffects":[{"effect":"Hepatic dysfunction","drugRate":"reported","severity":"serious"},{"effect":"Hepatic adenoma","drugRate":"reported","severity":"serious"},{"effect":"Peliosis hepatis","drugRate":"reported","severity":"serious"},{"effect":"Cholestatic jaundice","drugRate":"reported","severity":"serious"},{"effect":"Malignant liver tumors","drugRate":"reported","severity":"serious"},{"effect":"Hirsutism","drugRate":"reported","severity":"mild"},{"effect":"Edema","drugRate":"reported","severity":"mild"},{"effect":"Hair loss","drugRate":"reported","severity":"mild"},{"effect":"Voice change","drugRate":"reported","severity":"mild"},{"effect":"Hoarseness","drugRate":"reported","severity":"mild"},{"effect":"Sore throat","drugRate":"reported","severity":"mild"},{"effect":"Instability or deepening of pitch","drugRate":"reported","severity":"mild"},{"effect":"Hypertrophy of the clitoris","drugRate":"reported","severity":"mild"},{"effect":"Menstrual disturbances","drugRate":"reported","severity":"mild"},{"effect":"Spotting","drugRate":"reported","severity":"mild"},{"effect":"Alteration of the timing of the cycle","drugRate":"reported","severity":"mild"},{"effect":"Amenorrhea","drugRate":"reported","severity":"mild"},{"effect":"Cyclical bleeding","drugRate":"reported","severity":"mild"},{"effect":"Ovulation","drugRate":"reported","severity":"mild"},{"effect":"Flush","drugRate":"reported","severity":"mild"},{"effect":"Sweating","drugRate":"reported","severity":"mild"},{"effect":"Vaginal dryness","drugRate":"reported","severity":"mild"},{"effect":"Irritation","drugRate":"reported","severity":"mild"},{"effect":"Reduction in breast size","drugRate":"reported","severity":"mild"},{"effect":"Nervousness","drugRate":"reported","severity":"mild"},{"effect":"Emotional lability","drugRate":"reported","severity":"mild"},{"effect":"Abnormalities in semen volume","drugRate":"reported","severity":"mild"},{"effect":"Abnormalities in semen viscosity","drugRate":"reported","severity":"mild"},{"effect":"Abnormalities in sperm count","drugRate":"reported","severity":"mild"},{"effect":"Abnormalities in sperm motility","drugRate":"reported","severity":"mild"}],"contraindications":["Angina pectoris","Breastfeeding (mother)","Carcinoma of female breast","Chronic heart failure","Disease of liver","Epilepsy","Intermenstrual bleeding - irregular","Kidney disease","Migraine","Mixed hyperlipidemia","Porphyria","Pregnancy, function","Thromboembolic disorder"],"specialPopulations":{"Pregnancy":"Danazol administered orally to pregnant rats from the 6th through the 15th day of gestation at doses up to 250 mg/kg/day (7 to 15 times the human dose) did not result in drug-induced embryotoxicity or teratogenicity, nor difference in litter size, viability or weight of offspring compared to controls. In rabbits, the administration of danazol on days to 18 of gestation at doses of 60 mg/kg/day and above (2 to times the human dose) resulted ","Geriatric use":"Clinical studies of danazol did not include sufficient numbers of subjects aged 65 and over to determine the safety and effectiveness of danazol in elderly patients.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established."}},"trials":[],"aliases":[],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-04-17","unitCost":"$1.9662/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$718","description":"DANAZOL 100 MG CAPSULE","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DANAZOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:36:16.774328+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:36:22.532611+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:36:15.870624+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DANAZOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:36:22.956674+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:36:14.152804+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:36:14.152844+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNINGS Use of danazol in pregnancy is contraindicated. A sensitive test (e.g., beta subunit test if available) capable of determining early pregnancy is recommended immediately prior to start of therapy. Additionally a non-hormonal method of contraception should be used during therapy. If a patient becomes pregnant while taking danazol, administration of the drug should be discontinued and the patient should be apprised of the potential risk to the fetus. Exposure to danazol in utero may resul","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:36:14.152865+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:36:24.424048+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Androgen Receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:36:23.998693+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1479/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:36:23.661525+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA077246","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:36:14.152872+00:00"}},"allNames":"danzol","offLabel":[],"synonyms":["danazol","chronogyn","danatrol","danazolum","danocrine","danovaol","danzol","winobanin"],"timeline":[{"date":"1976-06-21","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"2007-04-19","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"}],"approvals":[{"date":"1976-06-21","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Danzol","ecosystem":[{"indication":"Endometriosis","otherDrugs":[{"name":"elagolix","slug":"elagolix","company":"Abbvie Inc "},{"name":"goserelin","slug":"goserelin","company":"Astrazeneca"},{"name":"leuprorelin","slug":"leuprorelin","company":""},{"name":"medroxyprogesterone","slug":"medroxyprogesterone","company":"Pharmacia And Upjohn"}],"globalPrevalence":null},{"indication":"Fibrocystic breast changes","otherDrugs":[],"globalPrevalence":null},{"indication":"Hereditary Angioedema Prevention","otherDrugs":[],"globalPrevalence":200000}],"mechanism":{"target":"Sex hormone-binding globulin","novelty":"Follow-on","targets":[{"gene":"SHBG","source":"DrugCentral","target":"Sex hormone-binding globulin","protein":"Sex hormone-binding globulin"},{"gene":"CYP2C9","source":"DrugCentral","target":"Cytochrome P450 2C9","protein":"Cytochrome P450 2C9"},{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"},{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"},{"gene":"ESR1","source":"DrugCentral","target":"Estrogen receptor","protein":"Estrogen receptor"},{"gene":"SLC6A3","source":"DrugCentral","target":"Sodium-dependent dopamine transporter","protein":"Sodium-dependent dopamine transporter"},{"gene":"SLC6A2","source":"DrugCentral","target":"Sodium-dependent noradrenaline transporter","protein":"Sodium-dependent noradrenaline transporter"},{"gene":"OPRM1","source":"DrugCentral","target":"Mu-type opioid receptor","protein":"Mu-type opioid receptor"}],"moaClass":"Androgen Receptor Agonists","modality":"Small Molecule","drugClass":"Androgen [EPC]","explanation":"","oneSentence":"","technicalDetail":"Danzol acts as a competitive inhibitor of sex hormone-binding globulin, leading to a decrease in the concentration of free estrogen in the plasma, which in turn reduces the growth and proliferation of estrogen-dependent tissues."},"commercial":{"launchDate":"1976","_launchSource":"DrugCentral (FDA 1976-06-21, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/779","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DANAZOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DANAZOL","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:23:53.554063","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:36:26.549637+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"alfentanil","drugSlug":"alfentanil","fdaApproval":"1986-12-29","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"alvimopan","drugSlug":"alvimopan","fdaApproval":"2008-05-20","patentExpiry":"Feb 12, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"anileridine","drugSlug":"anileridine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"buprenorphine","drugSlug":"buprenorphine","fdaApproval":"1981-12-29","patentExpiry":"Sep 5, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"butorphanol","drugSlug":"butorphanol","fdaApproval":"1978-08-22","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"cannabidiol","drugSlug":"cannabidiol","fdaApproval":"2018-06-25","patentExpiry":"Oct 13, 2035","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"cefapirin","drugSlug":"cefapirin","fdaApproval":"1974-03-12","relationship":"same-target"},{"drugName":"chlorpromazine","drugSlug":"chlorpromazine","fdaApproval":"1957-09-18","patentStatus":"Unknown","relationship":"same-target"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"danazol","indications":{"approved":[{"name":"Endometriosis","source":"DrugCentral","snomedId":129103003,"regulator":"FDA","eligibility":"Amenable to hormonal management"},{"name":"Fibrocystic breast changes","source":"DrugCentral","snomedId":27431007,"regulator":"FDA"},{"name":"Hereditary Angioedema Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","usPrevalence":null,"globalPrevalence":200000,"prevalenceMethod":"curated","prevalenceSource":"Int Arch Allergy Immunol, 2025 (PMID:39827848)"}],"offLabel":[{"name":"Gynecomastia","source":"DrugCentral","drugName":"DANAZOL","evidenceCount":22,"evidenceLevel":"moderate"},{"name":"Menorrhagia","source":"DrugCentral","drugName":"DANAZOL","evidenceCount":148,"evidenceLevel":"strong"},{"name":"Precocious puberty","source":"DrugCentral","drugName":"DANAZOL","evidenceCount":44,"evidenceLevel":"moderate"}],"pipeline":[]},"drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"alfentanil","brandName":"alfentanil","genericName":"alfentanil","approvalYear":"1986","relationship":"same-target"},{"drugId":"alvimopan","brandName":"alvimopan","genericName":"alvimopan","approvalYear":"2008","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"anileridine","brandName":"anileridine","genericName":"anileridine","approvalYear":"","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"buprenorphine","brandName":"buprenorphine","genericName":"buprenorphine","approvalYear":"1981","relationship":"same-target"},{"drugId":"butorphanol","brandName":"butorphanol","genericName":"butorphanol","approvalYear":"1978","relationship":"same-target"},{"drugId":"cannabidiol","brandName":"cannabidiol","genericName":"cannabidiol","approvalYear":"2018","relationship":"same-target"},{"drugId":"cefapirin","brandName":"cefapirin","genericName":"cefapirin","approvalYear":"1974","relationship":"same-target"},{"drugId":"chlorpromazine","brandName":"chlorpromazine","genericName":"chlorpromazine","approvalYear":"1957","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT03165734","phase":"PHASE3","title":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-06-26","conditions":["Primary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis"],"enrollment":399,"completionDate":"2027-07-30"},{"nctId":"NCT03312400","phase":"PHASE2","title":"Low-Dose Danazol for the Treatment of Telomere Related Diseases","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-02-08","conditions":["Telomere Disease"],"enrollment":40,"completionDate":"2027-10-29"},{"nctId":"NCT04576156","phase":"PHASE3","title":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Geron Corporation","startDate":"2021-04-12","conditions":["Myelofibrosis"],"enrollment":327,"completionDate":"2028-06-30"},{"nctId":"NCT07183787","phase":"PHASE2","title":"Letrozole vs Danazol for Endometriosis-Related Pain: Randomized Trial","status":"COMPLETED","sponsor":"Sidra Salman","startDate":"2019-04-10","conditions":["Endometriosis"],"enrollment":60,"completionDate":"2025-07-31"},{"nctId":"NCT04638517","phase":"PHASE2","title":"The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis","status":"TERMINATED","sponsor":"The University of Queensland","startDate":"2021-09-07","conditions":["Pulmonary Fibrosis","Telomere Shortening","Telomere Disease","Dyskeratosis Congenita"],"enrollment":29,"completionDate":"2025-01-16"},{"nctId":"NCT04873102","phase":"PHASE2","title":"Danazol for Treatment of Cytopenias in Patients With Cirrhosis","status":"RECRUITING","sponsor":"University of Southern California","startDate":"2024-08-01","conditions":["Cirrhosis, Liver","Cytopenia"],"enrollment":10,"completionDate":"2027-08-01"},{"nctId":"NCT06669221","phase":"","title":"Effectiveness of Early Intervention in Transfusion Independent Aplastic Anemia: a Retrospective Medical Claims Database Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-05","conditions":["Aplastic Anemia (AA)"],"enrollment":1603,"completionDate":"2023-11-03"},{"nctId":"NCT00953771","phase":"PHASE2","title":"Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2008-10","conditions":["Thrombotic Thrombocytopenic Purpura"],"enrollment":9,"completionDate":"2015-11-19"},{"nctId":"NCT06176911","phase":"PHASE2","title":"The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-12-05","conditions":["Immune Thrombocytopenia"],"enrollment":124,"completionDate":"2025-07-15"},{"nctId":"NCT04173494","phase":"PHASE3","title":"A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)","status":"COMPLETED","sponsor":"Sierra Oncology LLC - a GSK company","startDate":"2020-02-07","conditions":["Primary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis"],"enrollment":195,"completionDate":"2022-12-29"},{"nctId":"NCT04997811","phase":"PHASE2","title":"Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes","status":"UNKNOWN","sponsor":"Prof. Janet Dunn","startDate":"2021-12-21","conditions":["Myelodysplastic Syndromes (MDS)"],"enrollment":120,"completionDate":"2025-06-30"},{"nctId":"NCT05852847","phase":"PHASE2","title":"Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-05-16","conditions":["Immune Thrombocytopenia"],"enrollment":216,"completionDate":"2025-05"},{"nctId":"NCT05697471","phase":"PHASE3","title":"Comparisons of the Therapeutic Effects of Dienogest and Danazol on Endometriosis","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2023-02-25","conditions":["Endometriosis"],"enrollment":120,"completionDate":"2025-12-31"},{"nctId":"NCT04807309","phase":"PHASE1,PHASE2","title":"PRETELL: PREvention of TELomere-related Complications After Lung Transplant","status":"WITHDRAWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-01-01","conditions":["Short Telomere Length","Lung Transplant"],"enrollment":0,"completionDate":"2022-01-01"},{"nctId":"NCT01821677","phase":"PHASE2","title":"A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug) in the Treatment of Diabetic Macular Edema.","status":"COMPLETED","sponsor":"Ampio Pharmaceuticals. Inc.","startDate":"2013-02-26","conditions":["Diabetic Macular Edema"],"enrollment":354,"completionDate":"2015-01-23"},{"nctId":"NCT04058678","phase":"NA","title":"Effects of Telomerase Reactivation With Danazol in Ovarian Function.","status":"COMPLETED","sponsor":"IVI Madrid","startDate":"2020-01-30","conditions":["Ovarian Reserve"],"enrollment":19,"completionDate":"2021-12-31"},{"nctId":"NCT05494307","phase":"PHASE2","title":"The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-09-01","conditions":["Immune Thrombocytopenia"],"enrollment":228,"completionDate":"2024-02-28"},{"nctId":"NCT05471050","phase":"PHASE2","title":"The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-03-02","conditions":["Immune Thrombocytopenia"],"enrollment":120,"completionDate":"2023-06-01"},{"nctId":"NCT05281068","phase":"PHASE2","title":"The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2021-09-01","conditions":["ITP","Immune Thrombocytopenia"],"enrollment":120,"completionDate":"2023-12-30"},{"nctId":"NCT05353673","phase":"PHASE2","title":"The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2021-06-01","conditions":["Immune Thrombocytopenia","Blood Coagulation Disorders","Thrombocytopenia","Physiological Effects of Drugs"],"enrollment":120,"completionDate":"2023-02-01"},{"nctId":"NCT04757532","phase":"PHASE1","title":"Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2020-12-03","conditions":["Healthy Volunteers"],"enrollment":9,"completionDate":"2021-03-10"},{"nctId":"NCT03909763","phase":"PHASE2","title":"Combination of Danazole With Berberine in the Treatment of ITP","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2016-01-20","conditions":["Corticosteroid-resistant or Relapsed ITP"],"enrollment":55,"completionDate":"2021-06-30"},{"nctId":"NCT04481282","phase":"PHASE2","title":"The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2020-07-08","conditions":["Immune Thrombocytopenia"],"enrollment":40,"completionDate":"2021-07-31"},{"nctId":"NCT03352076","phase":"PHASE2","title":"Study to Determine Intraperitoneal,Tissue, Serum Concentrations of VML-0501 Following Five Days of Daily Vaginal Single Dose of VML-0501 (100 mg Danazol), in Comparison to Oral Danazol Capsules Daily 600 mg), in Women With Signs and Symptoms of Endometriosis Undergoing Laparoscopy","status":"COMPLETED","sponsor":"Viramal Limited","startDate":"2017-12-28","conditions":["Endometriosis"],"enrollment":30,"completionDate":"2020-05-26"},{"nctId":"NCT04324060","phase":"PHASE2,PHASE3","title":"A Randomized Trial of rhTPO Versus Placebo for Low/Intermediate-1 Risk MDS With Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-03-01","conditions":["Low/Intermediate Risk-1 MDS"],"enrollment":75,"completionDate":"2022-12-01"},{"nctId":"NCT04289207","phase":"PHASE2","title":"Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2020-03-01","conditions":["Immune Thrombocytopenia"],"enrollment":55,"completionDate":"2021-03-01"},{"nctId":"NCT00755326","phase":"PHASE2","title":"Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2007-04","conditions":["Osteoarthritis of the Knee"],"enrollment":92,"completionDate":"2010-07"},{"nctId":"NCT01001598","phase":"PHASE1,PHASE2","title":"Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita","status":"TERMINATED","sponsor":"Boston Children's Hospital","startDate":"2009-11","conditions":["Fanconi Anemia","Dyskeratosis Congenita"],"enrollment":5,"completionDate":"2014-05"},{"nctId":"NCT03710356","phase":"PHASE1,PHASE2","title":"Evaluating Efficacy and Safety of Danazol in Severe Hematologic or Pulmonary Disease Related to Telomeropathy","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-10-20","conditions":["Telomere Shortening","Telomere Length, Mean Leukocyte"],"enrollment":40,"completionDate":"2022-10-20"},{"nctId":"NCT01441037","phase":"PHASE1,PHASE2","title":"Danazol for Genetic Bone Marrow and Lung Disorders","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2011-07-19","conditions":["Aplastic Anemia"],"enrollment":27,"completionDate":"2016-11-14"},{"nctId":"NCT03563664","phase":"PHASE3","title":"Effect of Danazol on Endometrial αvβ3 Integrin Expression in Patients With Unexplained Recurrent Implantation Failure","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2015-08-01","conditions":["Unexplained Infertility"],"enrollment":38,"completionDate":"2017-08-15"},{"nctId":"NCT03460808","phase":"PHASE1,PHASE2","title":"The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-03-10","conditions":["Immune Thrombocytopenia"],"enrollment":200,"completionDate":"2023-01-01"},{"nctId":"NCT01433978","phase":"PHASE3","title":"A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2012-03-26","conditions":["Idiopathic Thrombocytopenic Purpura"],"enrollment":24,"completionDate":"2013-09"},{"nctId":"NCT01438840","phase":"PHASE3","title":"Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-02-16","conditions":["Chronic Thrombocytopenia","Immune Thrombocytopenia"],"enrollment":49,"completionDate":"2014-03"},{"nctId":"NCT01732445","phase":"PHASE2","title":"Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-04","conditions":["Anemia","Primary Myelofibrosis","Secondary Myelofibrosis"],"enrollment":14,"completionDate":"2017-08-10"},{"nctId":"NCT01667263","phase":"PHASE2","title":"The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2012-06-01","conditions":["Autoimmune Thrombocytopenia"],"enrollment":130,"completionDate":"2017-02-01"},{"nctId":"NCT01779232","phase":"PHASE4","title":"Danazol Treatment in Endometriosis Women Before IVF","status":"COMPLETED","sponsor":"Centre for Endocrinology and Reproductive Medicine, Italy","startDate":"2012-10","conditions":["Endometriosis","Ovarian Cysts","Infertility"],"enrollment":150,"completionDate":"2015-09"},{"nctId":"NCT02002403","phase":"PHASE2","title":"Efficacy and Safety Study to Evaluate Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2011-01","conditions":["Diabetic Macular Edema"],"enrollment":34,"completionDate":"2012-04"},{"nctId":"NCT00003946","phase":"PHASE2","title":"Danazol in Treating Patients With Advanced or Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"1999-08","conditions":["Endometrial Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT00758953","phase":"PHASE2","title":"Pain Associated With Endometriosis","status":"COMPLETED","sponsor":"Lumara Health, Inc.","startDate":"2007-02","conditions":["Endometriosis"],"enrollment":66,"completionDate":"2009-01"},{"nctId":"NCT01105793","phase":"PHASE2","title":"An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia","status":"COMPLETED","sponsor":"FemmePharma Global Healthcare, Inc.","startDate":"2010-06","conditions":["Moderate to Severe Cyclic Mastalgia"],"enrollment":20,"completionDate":"2011-06"},{"nctId":"NCT01162941","phase":"PHASE2","title":"Efficacy of Helicobacter Pylori Eradication, Anti-D and Danazol Combination in Steroid Dependant or Refractory Immune Thrombocytopenia (ITP)","status":"UNKNOWN","sponsor":"Cooperative Study Group A for Hematology","startDate":"2010-02","conditions":["Thrombocytopenia"],"enrollment":38,"completionDate":"2012-01"},{"nctId":"NCT00744276","phase":"PHASE2","title":"A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease","status":"COMPLETED","sponsor":"FemmePharma Global Healthcare, Inc.","startDate":"2007-01","conditions":["Fibrocystic Disease of Breast"],"enrollment":60,"completionDate":"2009-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"Danazol"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146564","MMSL":"3093","NDDF":"002116","UNII":"N29QWW3BUO","VUID":"4018233","CHEBI":"CHEBI:4315","VANDF":"4018233","INN_ID":"2556","RXNORM":"258343","UMLSCUI":"C0010961","chemblId":"CHEMBL1479","ChEMBL_ID":"CHEMBL1479","KEGG_DRUG":"D00289","DRUGBANK_ID":"DB01406","PDB_CHEM_ID":" QA1","PUBCHEM_CID":"28417","SNOMEDCT_US":"126124009","IUPHAR_LIGAND_ID":"6942","MESH_DESCRIPTOR_UI":"D003613"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.31 hours","clearance":"15.71 mL/min/kg","volumeOfDistribution":"5.18 L/kg"},"publicationCount":2684,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"G03XA01","allCodes":["G03XA01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 30","pmid":"41905994","title":"Identification of biomarkers associated with endoplasmic reticulum stress-related cell death in osteoporosis based on bulk and single-cell transcriptomic analyses and experimental validation.","journal":"Scientific reports"},{"date":"2026","pmid":"41880096","title":"Single-Cell Transcriptomics Reveals Biomarkers for NK Cell Dysfunction in Endometriosis-Associated Immune Dysregulation.","journal":"Mediators of inflammation"},{"date":"2026 Mar","pmid":"41842707","title":"Therapeutic Targets for Lung Squamous Cell Carcinoma: Proteome-Wide Mendelian Randomization and Potential Drug Prediction.","journal":"The clinical respiratory journal"},{"date":"2026 Mar 16","pmid":"41838173","title":"MPIG6B-related thrombocytopenia and myelofibrosis: A case report.","journal":"Annals of hematology"},{"date":"2026","pmid":"41743825","title":"Abdominal Wall Endometriosis Postcesarean Section: Diagnosis, Surgical Management, and Case Study of Extensive Uterine Adhesion.","journal":"Case reports in obstetrics and gynecology"}],"companionDiagnostics":[],"genericManufacturers":3,"_genericFilersChecked":true,"genericManufacturerList":["Am Therap","Barr","Lannett Co Inc"],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1976","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1976-06-21T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1998-05-29T00:00:00.000Z","mah":"BARR","brand_name_local":null,"application_number":"ANDA074582"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2007-10-29T00:00:00.000Z","mah":"LANNETT CO INC","brand_name_local":null,"application_number":"ANDA077246"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-03-15T00:00:00.000Z","mah":"LANNETT","brand_name_local":null,"application_number":"ANDA078214"},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:36:26.549637+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}